Abstract
We conducted a prospective study aimed at investigating the prognostic value of the dynamic of a-GVHD progression from cutaneous to visceral involvement. In 108 consecutive patients who underwent allogeneic HSCT, we classified a-GVHD according to a “GHVD skin dynamic”: 18/82 patients started Corticosteroid (CS) within 48 h (Group 1); 13/82 started CS within days 3–7 (Group 2); Group 3A (n 31) was defined when Skin GVHD Overall Grade 1, left untreated for 1 week, showed an increase in involved body surface area <5 %; Group 3B (n 20), was defined when Skin GVHD Overall Grade 1, left untreated at 1 week, had an increase in involved body surface area >5%. These four groups had distinctive 2-y OS. Patients could be then grouped into “poor risk” (Group 1 and Group 3B) and “good risk” (Group 2 and Group 3A). “Poor risk” had inferior OS in univariate and multivariate analysis, (HR 2.222; 95% CL: 1.017–4.855; p 0.04). Among the patients with skin-only Grade 1 GVHD, subgroup 3A had an OS of 75.1% versus 39.8% found in subgroup 3B (p = 0.03). The dynamic of skin GVHD may be used to classify a-GVHD and guide treatment in Overall Grade 1 skin-only GVHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
materials described in the manuscript, including all relevant raw data, are freely available to any researcher wishing to use them for non-commercial purposes, without breaching participant confidentiality. The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.
References
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell trans-plantation. N Engl J Med. 2010;363:2091–101.
Dalle JH, Giralt SA. Hepatic Veno-Occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22:400–9. https://doi.org/10.1016/j.bbmt.2015.09.024.
Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, et al. Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:310–20. https://doi.org/10.1016/j.jtct.2022.03.015.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. https://doi.org/10.1097/00007890-197410000-00001.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.
Martino R, Romero P, Subirá M, et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. Bone Marrow Transplant.1999;24:283–7. https://doi.org/10.1038/sj.bmt.1701899
MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–94. https://doi.org/10.1053/bbmt.2002.v8.pm12171485.
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64. https://doi.org/10.1046/j.1365-2141.1997.1112925.x.
Weisdorf DJ, Hurd D, Carter S, Howe C, Jensen LA, Wagner J, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–8. https://doi.org/10.1016/s1083-8791(03)00162-9.
Wallace AB. The exposure treatment of burns. Lancet. 1951;1:501–4. https://doi.org/10.1016/s0140-6736(51)91975-7.
Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Steroid treatment of acute graft-versus-host disease Grade I: a randomized trial. Haematologica. 2017;102:2125–33. https://doi.org/10.3324/haematol.2017.171157.
Gratwohl A, Brand R, Apperley J, Biezen AV, Bandini G, Devergie A, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (CLWP-EBMT). Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877–86. https://doi.org/10.1182/blood.V100.12.3877.
Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63. https://doi.org/10.1016/j.bbmt.2012.04.005.
Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47:1459–64. https://doi.org/10.1038/bmt.2012.45.
Carpenter PA, Macmillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am. 2010;57:273–95. https://doi.org/10.1016/j.pcl.2009.11.007.
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21:761–7. https://doi.org/10.1016/j.bbmt.2015.01.001.
McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126:113–20. https://doi.org/10.1182/blood-2015-03-636753.
Leotta S, Sapienza G, Camuglia MG, Avola G, Marco AD, Moschetti G, et al. Preliminary results of a combined score based on sIL2-Rα and TIM-3 levels assayed early after hematopoietic transplantation. Front Immunol. 2020;10:3158. https://doi.org/10.3389/fimmu.2019.03158.
Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2:e89798. https://doi.org/10.1172/jci.insight.89798.
Acknowledgements
We are grateful to dr Richard Brown for revising the English version of the manuscript.
Author information
Authors and Affiliations
Contributions
AC: wrote the paper; SL: planned the study; GAM: collected data and treated the patients; GG: collected data and treated the patients; GS: collected data and treated the patients; BE: collected data and treated the patients; DL: collected data and treated the patients; CP collected data and treated the patients; SF: collected data and treated the patients; LL: collected data and treated the patients. GiuliaG: verified overall plan and data analysis; GM: planned the study and analysed the data.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Milone, G., Leotta, S., Giuffrida, G. et al. Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment. Bone Marrow Transplant 59, 17–22 (2024). https://doi.org/10.1038/s41409-023-02107-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-023-02107-z